Stryker (SYK) Expected to Announce Quarterly Earnings on Thursday

Stryker (NYSE:SYK) is projected to issue its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of $3.14 per share and revenue of $6.0434 billion for the quarter. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS.Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same quarter last year, the firm posted $2.81 EPS. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. On average, analysts expect Stryker to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Stryker Stock Performance

NYSE:SYK opened at $387.84 on Thursday. Stryker has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average of $379.74 and a 200-day moving average of $379.16. The firm has a market cap of $148.27 billion, a price-to-earnings ratio of 51.37, a price-to-earnings-growth ratio of 2.74 and a beta of 0.94.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Analysts Set New Price Targets

SYK has been the subject of several research reports. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Barclays raised their price objective on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research report on Wednesday. UBS Group set a $408.00 price target on shares of Stryker in a report on Monday, October 13th. Evercore ISI cut their price target on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Finally, Wells Fargo & Company boosted their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $432.24.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Stryker

Several large investors have recently modified their holdings of SYK. Binnacle Investments Inc boosted its holdings in shares of Stryker by 26.1% during the 2nd quarter. Binnacle Investments Inc now owns 179 shares of the medical technology company’s stock worth $71,000 after buying an additional 37 shares during the period. Nebula Research & Development LLC bought a new stake in shares of Stryker during the 2nd quarter worth $219,000. HUB Investment Partners LLC bought a new stake in shares of Stryker during the 2nd quarter worth $253,000. Vivaldi Capital Management LP bought a new stake in shares of Stryker during the 2nd quarter worth $268,000. Finally, Two Sigma Securities LLC bought a new stake in shares of Stryker during the 2nd quarter worth $271,000. 77.09% of the stock is owned by institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.